Osteoarthritis (OA) is a major cause of suffering for millions of people. Investigating the disease directly on humans may be challenging. The aim of the present study is to investigate the advantages and limitations of the animal models currently used in OA research. The animal models are divided into induced and spontaneous. Induced models are further subdivided into surgical and chemical models, according to the procedure used to induce OA. Surgical induction of OA is the most commonly used procedure, which alters the exerted strain on the joint and/or alter load bearing leading to instability of the joint and induction of OA. Chemical models are generated by intra-articular injection of modifying factors or by systemically administering noxious agents, such as quinolones. Spontaneous models include naturally occurring and genetic models. Naturally occurring OA is described in certain species, while genetic models are developed by gene manipulation. Overall, there is no single animal model that is ideal for studying degenerative OA. However, in the present review, an attempt is made to clarify the most appropriate use of each model.

Small peptide catalysts containing modified histidine residues are reported that effect enantioselective acylation reactions. The catalysts described include octapeptide β-hairpins (e.g., 11) that exhibit high selectivities (up to k rel = 51), tetrapeptide β-turns (e.g., 7) that afford moderate selectivities (up to k rel = 28), and several simple derivatives of the modified histidine amino acid that do not exhibit appreciable enantioselectivity. Supporting structural studies (1H NMR and X-ray) are presented which lead to the proposal of a model in which catalyst rigidity and structural complexity contribute to higher degrees of enantioselection. A covalently rigidified octapeptide (20) is prepared through solid-phase Ru-catalyzed ring-closing metathesis; kinetic evaluation of this peptide reveals that substituents along the peptide backbone may be more important than covalent stabilization of a structural motif. Detailed kinetics studies on the most selective peptide catalysts are presented that suggest the reactions are first order in catalyst and substrate. Additional kinetic studies indicate unambiguously that enantioselectivities are due to specific acceleration of reaction for one substrate enantiomer, rather than the deceleration of the reaction for the other. The results are presented in the context of a possible enantiomer-specific hydrogen-bonding interaction in the stereochemistry-determining step for these processes.

Through fragment-based drug design focused on engaging the active site of IRAK4 and leveraging three-dimensional topology in a ligand-efficient manner, a micromolar hit identified from a screen of a Pfizer fragment library was optimized to afford IRAK4 inhibitors with nanomolar potency in cellular assays. The medicinal chemistry effort featured the judicious placement of lipophilicity, informed by co-crystal structures with IRAK4 and optimization of ADME properties to deliver clinical candidate PF-06650833 (compound 40). This compound displays a 5-unit increase in lipophilic efficiency from the fragment hit, excellent kinase selectivity, and pharmacokinetic properties suitable for oral administration.

Denosumab has been shown to reduce new vertebral, nonvertebral, and hip fractures in postmenopausal women with osteoporosis. In subjects who were treatment-naïve or previously treated with alendronate, denosumab was associated with greater gains in bone mineral density (BMD) and decreases in bone turnover markers when compared with alendronate-treated subjects. This trial was designed to compare the efficacy and safety of denosumab with risedronate over 12 months in postmenopausal women who transitioned from daily or weekly alendronate treatment and were considered to be suboptimally adherent to therapy. In this randomized, open-label study, postmenopausal women aged ≥55 years received denosumab 60 mg subcutaneously every 6 months or risedronate 150 mg orally every month for 12 months. Endpoints included percentage change from baseline in total hip BMD (primary endpoint), femoral neck, and lumbar spine BMD at month 12, and percentage change from baseline in sCTX-1 at months 1 and 6. Safety was also assessed. A total of 870 subjects were randomized (435, risedronate; 435, denosumab) who had a mean (SD) age of 67.7 (6.9) years, mean (SD) BMD T-scores of -1.6 (0.9), -1.9 (0.7), and -2.2 (1.2) at the total hip, femoral neck, and lumbar spine, respectively, and median sCTX-1 of 0.3 ng/mL at baseline. At month 12, denosumab significantly increased BMD compared with risedronate at the total hip (2.0% vs 0.5%), femoral neck (1.4% vs 0%), and lumbar spine (3.4% vs 1.1%; p<0.0001 at all sites). Denosumab significantly decreased sCTX-1 compared with risedronate at month 1 (median change from baseline of -78% vs -17%; p<0.0001) and month 6 (-61% vs -23%; p<0.0001). Overall and serious adverse events were similar between groups. In postmenopausal women who were suboptimally adherent to alendronate therapy, transitioning to denosumab was well tolerated and more effective than risedronate in increasing BMD and reducing bone turnover.

No abstract

Carbon nanodots are a new and intriguing class of fluorescent carbon nanomaterials and are considered a promising low cost, nontoxic alternative to traditional inorganic quantum dots in applications such as bioimaging, solar cells, photocatalysis, sensors and others. Despite the abundant available literature, a clear formation mechanism for carbon nanodots prepared hydrothermally from biomass precursors along with the origins of the light emission are still under debate. In this paper, we investigate the relationships between the chemical structure and optical properties of carbon nanodots prepared by the hydrothermal treatment of glucose. Our major finding is that the widely reported excitation-dependent emission originates from solvents used to suspend the as-prepared carbon nanodots, while emission from dry samples shows no excitation-dependence. Another important highlight is that the hydrothermal conversion of biomass-derivatives under subcritical conditions leads to a heterogeneous mixture of amorphous-like nanoparticles, carbon onion-type and crystalline carbons composed of at least three different phases. The potential chemical reaction pathways involved in the formation of these hydrothermal carbon products along with a comprehensive structural and optical characterization of these systems is also provided.

SummaryPersistence with and adherence to osteoporosis therapy are critical for fracture reduction. This non-interventional study is evaluating medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in Germany, Austria, Greece, and Belgium. Patients were representative of the PMO population and highly persistent with and adherent to denosumab at 12 months.IntroductionPersistence with and adherence to osteoporosis therapy are important for optimal treatment efficacy, namely fracture reduction. This ongoing, non-interventional study will evaluate medication-taking behavior of women with postmenopausal osteoporosis (PMO) receiving denosumab in routine practice in four European countries.MethodsThe study enrolled women who had been prescribed subcutaneous denosumab (60 mg every 6 months) in accordance with prescribing information and local guidelines. Persistence was defined as receiving the subsequent injection within 6 months + 8 weeks of the previous injection. Adherence was defined as receiving two consecutive injections within 6 months ± 4 weeks of each other. Medication coverage ratio (MCR) was calculated using the time a patient was covered with denosumab, as assessed from prescription records. Treatment was assigned prior to and independently of enrollment; outcomes are recorded during routine practice.ResultsThese planned 12-month interim analyses included data from 1500 patients from 141 sites. Mean age was 66.4–72.4 years, mean baseline total hip T-scores ranged from −2.0 to −2.1 and femoral neck T-scores from −2.2 to −2.6, and 30.7–62.1 % of patients had prior osteoporotic fracture. Persistence was 87.0–95.3 %, adherence 82.7–89.3 %, and MCR 91.3–95.4 %. In a univariate analysis, increased age, decreased mobility, and increased distance to the clinic were associated with significantly decreased persistence; parental history of hip fracture was associated with significantly increased persistence.ConclusionsThese data extend the real-world evidence regarding persistence with and adherence to denosumab, both of which are critical for favorable clinical outcomes, including fracture risk reduction.Electronic supplementary materialThe online version of this article (doi:10.1007/s00198-015-3164-4) contains supplementary material, which is available to authorized users.

No abstract